Charlotte Charpentier

InstitutionUniversité Paris Diderot
AddressParis
France
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 11 Covid-19 publications, with a maximum of 2 publications in February 2021 and August 2021
    All Publications
    Bar chart showing 138 publications over 17 distinct years, with a maximum of 19 publications in 2011
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Teyssou E, Delagrèverie H, Visseaux B, Lambert-Niclot S, Brichler S, Ferre V, Marot S, Jary A, Todesco E, Schnuriger A, Ghidaoui E, Abdi B, Akhavan S, Houhou-Fidouh N, Charpentier C, Morand-Joubert L, Boutolleau D, Descamps D, Calvez V, Marcelin AG, Soulie C. The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients. J Infect. 2021 10; 83(4):e1-e3. PMID: 34419559.
      Citations: 13     Fields:    Translation:Humans
    2. Peiffer-Smadja N, Bridier-Nahmias A, Ferré VM, Charpentier C, Garé M, Rioux C, Allemand A, Lavallée P, Ghosn J, Kramer L, Descamps D, Yazdanpanah Y, Visseaux B. Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2. Viruses. 2021 08 19; 13(8). PMID: 34452507.
      Citations: 3     Fields:    Translation:Humans
    3. Husain M, Rachline A, Cousien A, Rolland S, Rouzaud C, Ferre VM, Gomez MV, Le Teurnier M, Wicky-Thisse M, Descamps D, Yazdanpanah Y, Charpentier C, Pasquet-Cadre A. Impact of the COVID-19 pandemic on the homeless: results from a retrospective closed cohort in France (March-May 2020). Clin Microbiol Infect. 2021 Oct; 27(10):1520.e1-1520.e5. PMID: 34111590.
      Citations: 1     Fields:    Translation:Humans
    4. Charpentier C, Pellissier G, Ichou H, Ferré VM, Larfi I, Phung BC, Vallois D, LeGac S, Aubier M, Descamps D, Fidouh-Houhou N, Bouvet E. Contribution of rapid lateral flow assays from capillary blood specimens to the diagnosis of COVID-19 in symptomatic healthcare workers: a pilot study in a university hospital, Paris, France. Diagn Microbiol Infect Dis. 2021 Oct; 101(2):115430. PMID: 34229244.
      Citations:    Fields:    Translation:Humans
    5. Teyssou E, Soulie C, Visseaux B, Lambert-Niclot S, Ferre V, Marot S, Jary A, Sayon S, Zafilaza K, Leducq V, Schnuriger A, Abdi B, Wirden M, Houhou-Fidouh N, Charpentier C, Morand-Joubert L, Burrel S, Descamps D, Calvez V, Marcelin AG. The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients. J Infect. 2021 Jul; 83(1):119-145. PMID: 33932451.
      Citations: 4     Fields:    Translation:Humans
    6. Citations: 1     Fields:    Translation:Humans
    7. Visseaux B, Collin G, Houhou-Fidouh N, Le Hingrat Q, Ferré VM, Damond F, Ichou H, Descamps D, Charpentier C. Evaluation of three extraction-free SARS-CoV-2 RT-PCR assays: A feasible alternative approach with low technical requirements. J Virol Methods. 2021 05; 291:114086. PMID: 33577957.
      Citations: 3     Fields:    
    8. Tubiana S, Burdet C, Houhou N, Thy M, Manchon P, Blanquart F, Charpentier C, Guedj J, Alavoine L, Behillil S, Leclercq A, Lucet JC, Yazdanpanah Y, Attia M, Demeret C, Rose T, Bielicki JA, Bruijning-Verhagen P, Goossens H, Descamps D, van der Werf S, Lina B, Duval X. High-risk exposure without personal protective equipment and infection with SARS-CoV-2 in-hospital workers - The CoV-CONTACT cohort. J Infect. 2021 05; 82(5):186-230. PMID: 33545165.
      Citations: 2     Fields:    Translation:Humans
    9. Hingrat QL, Visseaux B, Laouenan C, Tubiana S, Bouadma L, Yazdanpanah Y, Duval X, Burdet C, Ichou H, Damond F, Bertine M, Benmalek N, Choquet C, Timsit JF, Ghosn J, Charpentier C, Descamps D, Houhou-Fidouh N. Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives. Clin Microbiol Infect. 2020 12 08. PMID: 33307227.
      Citations: 13     Fields:    
    10. Charpentier C, Ichou H, Damond F, Bouvet E, Chaix ML, Ferré V, Delaugerre C, Mahjoub N, Larrouy L, Le Hingrat Q, Visseaux B, Mackiewicz V, Descamps D, Fidouh-Houhou N. Performance evaluation of two SARS-CoV-2 IgG/IgM rapid tests (Covid-Presto and NG-Test) and one IgG automated immunoassay (Abbott). J Clin Virol. 2020 11; 132:104618. PMID: 32919222.
      Citations: 6     Fields:    Translation:Humans
    11. Battesti G, El Khalifa J, Abdelhedi N, Ferre V, Bouscarat F, Picard-Dahan C, Brunet-Possenti F, Collin G, Lavaud J, Le Bozec P, Rousselot M, Tournier A, Lheure C, Couvelard A, Hacein-Bey-Abina S, Abina AM, Charpentier C, Mignot S, Nicaise P, Descamps D, Deschamps L, Descamps V. New insights in COVID-19-associated chilblains: A comparative study with chilblain lupus erythematosus. J Am Acad Dermatol. 2020 Oct; 83(4):1219-1222. PMID: 32622895.
      Citations: 10     Fields:    Translation:HumansCellsPHPublic Health
    12. Ferré VM, Gbeasor-Komlanvi FA, Collin G, Dagnra AC, Le Hingrat Q, Jaquet A, Salou M, Descamps D, Charpentier C, Ekouevi DK. Prevalence of Human Papillomavirus, Human Immunodeficiency Virus, and Other Sexually Transmitted Infections Among Men Who Have Sex With Men in Togo: A National Cross-sectional Survey. Clin Infect Dis. 2019 08 30; 69(6):1019-1026. PMID: 30520971.
      Citations: 7     Fields:    Translation:HumansCellsPHPublic Health
    13. Castain L, Perrier M, Charpentier C, Palich R, Desire N, Wirden M, Descamps D, Sayon S, Landman R, Valantin MA, Joly V, Peytavin G, Yazdanpanah Y, Katlama C, Calvez V, Marcelin AG, Todesco E. New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations. J Antimicrob Chemother. 2019 07 01; 74(7):2019-2023. PMID: 31050739.
      Citations: 2     Fields:    Translation:HumansCells
    14. Mboumba Bouassa RS, Mossoro-Kpinde CD, Gody JC, Veyer D, Péré H, Matta M, Robin L, Grésenguet G, Charpentier C, Bélec L. High predictive efficacy of integrase strand transfer inhibitors in perinatally HIV-1-infected African children in therapeutic failure of first- and second-line antiretroviral drug regimens recommended by the WHO. J Antimicrob Chemother. 2019 07 01; 74(7):2030-2038. PMID: 30891603.
      Citations:    Fields:    Translation:HumansCells
    15. Perrier M, Castain L, Regad L, Todesco E, Landman R, Visseaux B, Yazdanpanah Y, Rodriguez C, Joly V, Calvez V, Marcelin AG, Descamps D, Charpentier C. HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen. J Antimicrob Chemother. 2019 06 01; 74(6):1679-1692. PMID: 30768160.
      Citations: 4     Fields:    Translation:HumansCells
    16. Marcelin AG, Grude M, Charpentier C, Bellecave P, Le Guen L, Pallier C, Raymond S, Mirand A, Bocket L, Fofana DB, Delaugerre C, Nguyen T, Montès B, Jeulin H, Mourez T, Fafi-Kremer S, Amiel C, Roussel C, Dina J, Trabaud MA, Le Guillou-Guillemette H, Vallet S, Signori-Schmuck A, Maillard A, Ferre V, Descamps D, Calvez V, Flandre P. Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients. J Antimicrob Chemother. 2019 05 01; 74(5):1368-1375. PMID: 30789205.
      Citations: 1     Fields:    Translation:HumansCells
    17. Assoumou L, Bocket L, Pallier C, Grude M, Ait-Namane R, Izopet J, Raymond S, Charpentier C, Visseaux B, Wirden M, Trabaud MA, Le Guillou-Guillemette H, Allaoui C, Henquell C, Krivine A, Dos Santos G, Delamare C, Bouvier-Alias M, Montes B, Ferre V, De Monte A, Signori-Schmuck A, Maillard A, Morand-Joubert L, Tumiotto C, Fafi-Kremer S, Amiel C, Barin F, Marque-Juillet S, Courdavault L, Vallet S, Beby-Defaux A, de Rougemont A, Fenaux H, Avettand-Fenoel V, Allardet-Servent A, Plantier JC, Peytavin G, Calvez V, Chaix ML, Descamps D. Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France. J Antimicrob Chemother. 2019 05 01; 74(5):1417-1424. PMID: 30753724.
      Citations: 2     Fields:    Translation:HumansCells
    18. Le Hingrat Q, Charpentier C, Ghosn J, Thiébaut R, Peytavin G, Descamps D, Matheron S. New insights are game-changers in HIV-2 disease management. Lancet HIV. 2019 04; 6(4):e214. PMID: 30942186.
      Citations:    Fields:    Translation:HumansCells
    19. Brunet-Possenti F, Deschamps L, Charpentier C. Use of Combination Systemic-Intratumoral HPV Vaccine to Treat Cutaneous Basaloid Squamous Cell Carcinomas. JAMA Dermatol. 2019 01 01; 155(1):123-124. PMID: 30540339.
      Citations: 1     Fields:    Translation:Humans
    20. Pouga L, Santoro MM, Charpentier C, Di Carlo D, Romeo I, Artese A, Alcaro S, Antinori A, Wirden M, Perno CF, Ambrosio FA, Calvez V, Descamps D, Marcelin AG, Ceccherini-Silberstein F, Lambert-Niclot S. New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T). Chem Biol Drug Des. 2019 01; 93(1):50-59. PMID: 30103267.
      Citations:    Fields:    Translation:HumansCells
    21. Alessandri-Gradt E, Charpentier C, Leoz M, Mourez T, Descamps D, Plantier JC. Impact of natural polymorphisms of HIV-1 non-group M on genotypic susceptibility to the attachment inhibitor fostemsavir. J Antimicrob Chemother. 2018 10 01; 73(10):2716-2720. PMID: 30032194.
      Citations: 3     Fields:    Translation:HumansCells
    22. Matheron S, Descamps D, Gallien S, Besseghir A, Sellier P, Blum L, Mortier E, Charpentier C, Tubiana R, Damond F, Peytavin G, Ponscarme D, Collin F, Brun-Vezinet F, Chene G. First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2). Clin Infect Dis. 2018 09 28; 67(8):1161-1167. PMID: 29590335.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    23. Cazals N, Le Hingrat Q, Abraham B, Da Silva P, Guindre L, Goffart S, Damond F, Visseaux B, Charpentier C, Ranger-Rogez S, Descamps D. HIV-2 Primary Infection in a French 69-Year-Old Bisexual Man. Open Forum Infect Dis. 2018 Oct; 5(10):ofy223. PMID: 30310823.
      Citations:    
    24. Mariaggi AA, Péré H, Perrier M, Visseaux B, Collin G, Veyer D, Le Hingrat Q, Ferré VM, Joly V, Couvelard A, Bucau M, Davitian C, Descamps D, Abramowitz L, Charpentier C. Presence of Human Papillomavirus (HPV) Apolipoprotein B Messenger RNA Editing, Catalytic Polypeptide-Like 3 (APOBEC)-Related Minority Variants in HPV-16 Genomes From Anal and Cervical Samples but Not in HPV-52 and HPV-58. J Infect Dis. 2018 08 24; 218(7):1027-1036. PMID: 29788374.
      Citations: 3     Fields:    Translation:HumansCells
    25. Perrier M, Désiré N, Storto A, Todesco E, Rodriguez C, Bertine M, Le Hingrat Q, Visseaux B, Calvez V, Descamps D, Marcelin AG, Charpentier C. Evaluation of different analysis pipelines for the detection of HIV-1 minority resistant variants. PLoS One. 2018; 13(6):e0198334. PMID: 29856864.
      Citations: 5     Fields:    Translation:HumansCells
    26. Charpentier C, Peytavin G, Lê MP, Joly V, Cabras O, Perrier M, Le Gac S, Phung B, Yazdanpanah Y, Descamps D, Landman R. High virological suppression regardless of the genotypic susceptibility score after switching to a dolutegravir-based regimen: week 48 results in an observational cohort. J Antimicrob Chemother. 2018 06 01; 73(6):1665-1671. PMID: 29528412.
      Citations: 3     Fields:    Translation:HumansCells
    27. Unal G, Alessandri-Gradt E, Leoz M, Pavie J, Lefèvre C, Panjo H, Charpentier C, Descamps D, Barin F, Simon F, Meyer L, Plantier JC. Human Immunodeficiency Virus Type 1 Group O Infection in France: Clinical Features and Immunovirological Response to Antiretrovirals. Clin Infect Dis. 2018 05 17; 66(11):1785-1793. PMID: 29272369.
      Citations:    Fields:    Translation:HumansCells
    28. Raymond S, Nicot F, Pallier C, Bellecave P, Maillard A, Trabaud MA, Morand-Joubert L, Rodallec A, Amiel C, Mourez T, Bocket L, Beby-Defaux A, Bouvier-Alias M, Lambert-Niclot S, Charpentier C, Malve B, Mirand A, Dina J, Le Guillou-Guillemette H, Marque-Juillet S, Signori-Schmuck A, Barin F, Si-Mohamed A, Avettand Fenoel V, Roussel C, Calvez V, Saune K, Marcelin AG, Rodriguez C, Descamps D, Izopet J. Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen. Clin Infect Dis. 2018 05 02; 66(10):1588-1594. PMID: 29244143.
      Citations: 6     Fields:    Translation:HumansCells
    29. Storto A, Visseaux B, Bertine M, Le Hingrat Q, Collin G, Damond F, Khuong MA, Blum L, Tubiana R, Karmochkine M, Cazanave C, Matheron S, Descamps D, Charpentier C. Minority resistant variants are also present in HIV-2-infected antiretroviral-naive patients. J Antimicrob Chemother. 2018 05 01; 73(5):1173-1176. PMID: 29415189.
      Citations: 3     Fields:    Translation:HumansCells
    30. Charpentier C, Malet I, Andre-Garnier E, Storto A, Bocket L, Amiel C, Morand-Joubert L, Tumiotto C, Nguyen T, Maillard A, Rodallec A, Leoz M, Montes B, Schneider V, Plantier JC, Dina J, Pallier C, Mirand A, Roussel C, Signori-Schmuck A, Raymond S, Calvez V, Delaugerre C, Marcelin AG, Descamps D. Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen. J Antimicrob Chemother. 2018 04 01; 73(4):1039-1044. PMID: 29342281.
      Citations: 10     Fields:    Translation:HumansCells
    31. Le Hingrat Q, Perrier M, Collin G, Drumard S, Storto A, Bertine M, Larrouy L, Matheron S, Damond F, Charpentier C, Descamps D, Visseaux B. Efficiency of HIV-2 cultures from clinical isolates is enhanced after purification by anti-CD44 microbeads. J Virol Methods. 2018 07; 257:12-15. PMID: 29588254.
      Citations:    Fields:    Translation:HumansCells
    32. Ségéral O, Nerrienet E, Neth S, Spire B, Khol V, Ferradini L, Sarun S, Mom C, Ngin S, Charpentier C, Men P, Mora M, Mean Chhi V, Ly P, Saphonn V. Positive Virological Outcomes of HIV-Infected Patients on Protease Inhibitor-Based Second-Line Regimen in Cambodia: The ANRS 12276 2PICAM Study. Front Public Health. 2018; 6:63. PMID: 29662875.
      Citations: 1     
    33. Charpentier C, Descamps D. Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations. Viruses. 2018 01 18; 10(1). PMID: 29346270.
      Citations: 9     Fields:    Translation:HumansCells
    34. Perrier M, Visseaux B, Landman R, Joly V, Todesco E, Yazdanpanah Y, Calvez V, Marcelin AG, Descamps D, Charpentier C. No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir. J Antimicrob Chemother. 2018 Jan 01; 73(1):173-176. PMID: 29077926.
      Citations: 7     Fields:    Translation:HumansCells
    35. Perrier M, Bertine M, Le Hingrat Q, Joly V, Visseaux B, Collin G, Landman R, Yazdanpanah Y, Descamps D, Charpentier C. Prevalence of gag mutations associated with in vitro resistance to capsid inhibitor GS-CA1 in HIV-1 antiretroviral-naive patients. J Antimicrob Chemother. 2017 10 01; 72(10):2954-2955. PMID: 29091184.
      Citations: 14     Fields:    Translation:HumansCells
    36. Charpentier C, Montes B, Perrier M, Meftah N, Reynes J. HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual therapy dolutegravir?+?lamivudine in the maintenance DOLULAM pilot study. J Antimicrob Chemother. 2017 10 01; 72(10):2831-2836. PMID: 29091218.
      Citations: 8     Fields:    Translation:HumansCells
    37. Wirden M, Larrouy L, Mahjoub N, Todesco E, Damond F, Delagreverie H, Akhavan S, Charpentier C, Chaix ML, Descamps D, Calvez V, Marcelin AG. Multicenter comparison of the new Cobas 6800 system with Cobas Ampliprep/Cobas TaqMan and Abbott RealTime for the quantification of HIV, HBV and HCV viral load. J Clin Virol. 2017 11; 96:49-53. PMID: 28950186.
      Citations: 6     Fields:    Translation:HumansCells
    38. Douine M, Mosnier E, Le Hingrat Q, Charpentier C, Corlin F, Hureau L, Adenis A, Lazrek Y, Niemetsky F, Aucouturier AL, Demar M, Musset L, Nacher M. Illegal gold miners in French Guiana: a neglected population with poor health. BMC Public Health. 2017 07 17; 18(1):23. PMID: 28716015.
      Citations: 17     Fields:    Translation:HumansPHPublic Health
    39. Visseaux B, Burdet C, Voiriot G, Lescure FX, Chougar T, Brugière O, Crestani B, Casalino E, Charpentier C, Descamps D, Timsit JF, Yazdanpanah Y, Houhou-Fidouh N. Prevalence of respiratory viruses among adults, by season, age, respiratory tract region and type of medical unit in Paris, France, from 2011 to 2016. PLoS One. 2017; 12(7):e0180888. PMID: 28708843.
      Citations: 20     Fields:    Translation:HumansCells
    40. Perrier M, Charpentier C, Peytavin G, Lê M, Blondel L, Visseaux B, Joly V, Pinto A, Matheron S, Yazdanpanah Y, Descamps D, Landman R. Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort. J Antimicrob Chemother. 2017 06 01; 72(6):1745-1751. PMID: 28186251.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    41. Papot E, Landman R, Louni F, Charpentier C, Peytavin G, Certain A, Fradet C, Castro DR, Preau M, Goujard C, Yeni P, Yazdanpanah Y. Budget impact of antiretroviral therapy in a French clinic cohort. AIDS. 2017 06 01; 31(9):1271-1279. PMID: 28323753.
      Citations: 4     Fields:    Translation:Humans
    42. Madelain V, Le MP, Champenois K, Charpentier C, Landman R, Joly V, Yeni P, Descamps D, Yazdanpanah Y, Peytavin G. Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study. J Antimicrob Chemother. 2017 04 01; 72(4):1137-1146. PMID: 28065890.
      Citations: 4     Fields:    Translation:HumansCells
    43. Rhee SY, Varghese V, Holmes SP, Van Zyl GU, Steegen K, Boyd MA, Cooper DA, Nsanzimana S, Saravanan S, Charpentier C, de Oliveira T, Etiebet MA, Garcia F, Goedhals D, Gomes P, Günthard HF, Hamers RL, Hoffmann CJ, Hunt G, Jiamsakul A, Kaleebu P, Kanki P, Kantor R, Kerschberger B, Marconi VC, D'amour Ndahimana J, Ndembi N, Ngo-Giang-Huong N, Rokx C, Santoro MM, Schapiro JM, Schmidt D, Seu L, Sigaloff KCE, Sirivichayakul S, Skhosana L, Sunpath H, Tang M, Yang C, Carmona S, Gupta RK, Shafer RW. Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration. EBioMedicine. 2017 Apr; 18:225-235. PMID: 28365230.
      Citations: 17     Fields:    Translation:HumansCells
    44. Visseaux B, Collin G, Ichou H, Charpentier C, Bendhafer S, Dumitrescu M, Allal L, Cojocaru B, Desfrère L, Descamps D, Mandelbrot L, Houhou-Fidouh N. Usefulness of multiplex PCR methods and respiratory viruses' distribution in children below 15 years old according to age, seasons and clinical units in France: A 3 years retrospective study. PLoS One. 2017; 12(2):e0172809. PMID: 28235002.
      Citations: 10     Fields:    Translation:HumansCells
    45. Wirden M, Charpentier C, Tubiana R, Le MP, Desire N, Dionou S, Pichon F, Valantin MA, Yasdanpanah Y, Descamps D, Peytavin G, Katlama C, Calvez V, Marcelin AG. HIV-1 diagnosis with unquantifiable viraemia: don't be naive, look for antiretroviral drugs. J Antimicrob Chemother. 2017 02; 72(2):630-632. PMID: 27999067.
      Citations:    Fields:    Translation:HumansCells
    46. Benmoussa N, Charpentier C, Mariaggi AA, Collin G, Descamps D, Hourseau M, Barry B, Albert S, Picard A, Conan P, Charlier P. HPV 16 in squamous cell carcinoma of 19th century tonsils. Lancet Oncol. 2016 11; 17(11):e477-e478. PMID: 27819244.
      Citations:    Fields:    Translation:HumansCells
    47. Visseaux B, Mortier E, Houhou-Fidouh N, Brichler S, Collin G, Larrouy L, Charpentier C, Descamps D. Zika virus in the female genital tract. Lancet Infect Dis. 2016 11; 16(11):1220. PMID: 27788975.
      Citations: 19     Fields:    Translation:HumansCells
    48. Senard O, Burdet C, Visseaux B, Charpentier C, Le Gac S, Julia Z, Lariven S, Descamps D, Yazdanpanah Y, Yeni P, Joly V. Epidemiological Profile of Newly Diagnosed HIV-Infected Patients in Northern Paris: A Retrospective Study. AIDS Res Hum Retroviruses. 2017 01; 33(1):11-16. PMID: 27476681.
      Citations: 1     Fields:    Translation:HumansCells
    49. Visseaux B, Damond F, Matheron S, Descamps D, Charpentier C. Hiv-2 molecular epidemiology. Infect Genet Evol. 2016 12; 46:233-240. PMID: 27530215.
      Citations: 23     Fields:    Translation:HumansCells
    50. Bertine M, Visseaux B, Storto A, Collin G, Matheron S, Descamps D, Charpentier C. HIV-2 Vif Diversity Among Defective and Nondefective Sequences. J Acquir Immune Defic Syndr. 2016 May 01; 72(1):e9-e11. PMID: 26689972.
      Citations:    Translation:HumansCells
    51. Delory T, Papot E, Rioux C, Charpentier C, Auge-Courtoi C, Michard F, Peytavin G, Descamps D, Matheron S, Yazdanpanah Y. Foscarnet, zidovudine and dolutegravir combination efficacy and tolerability for late stage HIV salvage therapy: A case-series experience. J Med Virol. 2016 Jul; 88(7):1204-10. PMID: 26636432.
      Citations: 3     Fields:    Translation:HumansCells
    52. Jenabian MA, Talla F, Talla P, Mbopi-Kéou FX, Charpentier C, Kane CT, Bélec L. Pitfalls of antiretroviral drug resistance genotyping of HIV-1 Group M and Group N from Cameroon by sequenced-based assays. Niger Med J. 2015 Nov-Dec; 56(6):420-4. PMID: 26903701.
      Citations: 1     Fields:    
    53. Visseaux B, Charpentier C, Ozanne A, Nizard A, Drumard S, Fagard C, Glohi D, Damond F, Brun-Vézinet F, Matheron S, Descamps D. Tropism distribution among antiretroviral-naive HIV-2-infected patients. AIDS. 2015 Oct 23; 29(16):2209-12. PMID: 26544584.
      Citations: 1     Fields:    Translation:HumansCells
    54. Cuzin L, Pugliese P, Sauné K, Allavena C, Ghosn J, Cottalorda J, Rodallec A, Chaix ML, Fafi-Kremer S, Soulié C, Ouka M, Charpentier C, Bocket L, Mirand A, Guiguet M. Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy. AIDS. 2015 Aug 24; 29(13):1665-71. PMID: 26372277.
      Citations: 17     Fields:    Translation:Humans
    55. Charpentier C, Camacho R, Ruelle J, Eberle J, Gürtler L, Pironti A, Stürmer M, Brun-Vézinet F, Kaiser R, Descamps D, Obermeier M. HIV-2EU-Supporting Standardized HIV-2 Drug-Resistance Interpretation in Europe: An Update. Clin Infect Dis. 2015 Oct 15; 61(8):1346-7. PMID: 26187019.
      Citations: 8     Fields:    Translation:HumansCells
    56. Péré H, Roques P, Talla F, Meillo H, Charpentier C, Bélec L. Sustained virological failure in Cameroonese patient infected by HIV-1 group N evidenced by sequence-based genotyping assay. AIDS. 2015 Jun 19; 29(10):1267-9. PMID: 26035326.
      Citations: 1     Fields:    Translation:HumansCells
    57. Bertine M, Charpentier C, Visseaux B, Storto A, Collin G, Larrouy L, Damond F, Matheron S, Brun-Vézinet F, Descamps D. High level of APOBEC3F/3G editing in HIV-2 DNA vif and pol sequences from antiretroviral-naive patients. AIDS. 2015 Apr 24; 29(7):779-84. PMID: 25985400.
      Citations: 5     Fields:    Translation:HumansCells
    58. Charpentier C, Lee GQ, Rodriguez C, Visseaux B, Storto A, Fagard C, Molina JM, Katlama C, Yazdanpanah Y, Harrigan PR, Descamps D. Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response. J Antimicrob Chemother. 2015 Jul; 70(7):2090-6. PMID: 25755001.
      Citations: 10     Fields:    Translation:HumansCells
    59. Loubet P, Charpentier C, Visseaux B, Borbor A, Nuta C, Adu E, Chapplain JM, Baysah M, Tattevin P, Yazdanpanah Y, Descamps D. Prevalence of HIV-1 drug resistance among patients failing first-line ART in Monrovia, Liberia: a cross-sectional study. J Antimicrob Chemother. 2015; 70(6):1881-4. PMID: 25698771.
      Citations: 6     Fields:    Translation:HumansCells
    60. Descamps D, Peytavin G, Visseaux B, Tubiana R, Damond F, Campa P, Charpentier C, Khuong-Josses MA, Duvivier C, Karmochkine M, Lukiana T, Matheron S. Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program. Clin Infect Dis. 2015 May 15; 60(10):1521-7. PMID: 25690598.
      Citations: 9     Fields:    Translation:HumansCells
    61. Lê MP, Landman R, Koulla-Shiro S, Charpentier C, Sow PS, Diallo MB, Ngom Gueye NF, Ngolle M, Le Moing V, Eymard-Duvernay S, Benalycherif A, Delaporte E, Girard PM, Peytavin G. Tenofovir plasma concentrations related to estimated glomerular filtration rate changes in first-line regimens in African HIV-infected patients: ANRS 12115 DAYANA substudy. J Antimicrob Chemother. 2015 May; 70(5):1517-21. PMID: 25583749.
      Citations: 6     Fields:    Translation:HumansCells
    62. Fourati S, Charpentier C, Amiel C, Morand-Joubert L, Reigadas S, Trabaud MA, Delaugerre C, Nicot F, Rodallec A, Maillard A, Mirand A, Jeulin H, Montès B, Barin F, Bettinger D, Le Guillou-Guillemette H, Vallet S, Signori-Schmuck A, Descamps D, Calvez V, Flandre P, Marcelin AG. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients. J Antimicrob Chemother. 2015 May; 70(5):1507-12. PMID: 25558077.
      Citations: 21     Fields:    Translation:HumansCells
    63. Soulie C, Peytavin G, Charpentier C, Lambert-Niclot S, Sayon S, Visseaux B, Simon A, Katlama C, Yazdanpanah Y, Descamps D, Calvez V, Marcelin AG. Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological Response. AIDS Res Hum Retroviruses. 2015 May; 31(5):475-8. PMID: 25420695.
      Citations: 1     Fields:    Translation:HumansCells
    64. Marcelin AG, Charpentier C, Wirden M, Descamps D, Calvez V. Less frequent follow-up in routine care than in trials does not impact resistance selection in patients failing DRV/r or ATV/r first line treatment. J Int AIDS Soc. 2014; 17(4 Suppl 3):19744. PMID: 25397489.
      Citations:    Fields:    
    65. Deuzing IP, Charpentier C, Wright DW, Matheron S, Paton J, Frentz D, van de Vijver DA, Coveney PV, Descamps D, Boucher CA, Beerens N. Mutation V111I in HIV-2 reverse transcriptase increases the fitness of the nucleoside analogue-resistant K65R and Q151M viruses. J Virol. 2015 Jan; 89(1):833-43. PMID: 25355888.
      Citations: 7     Fields:    Translation:HumansCells
    66. Fofana DB, Charpentier C, Maïga AI, Lambert-Niclot S, Sayon S, Désiré N, Simon A, Yazdanpanah Y, Katlama C, Descamps D, Calvez V, Marcelin AG, Soulié C. Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes. J Antimicrob Chemother. 2015 Jan; 70(1):130-5. PMID: 25270328.
      Citations: 1     Fields:    Translation:HumansCells
    67. Visseaux B, Charpentier C, Rouard C, Fagard C, Glohi D, Tubiana R, Damond F, Brun-Vézinet F, Matheron S, Descamps D. HIV-2 X4 tropism is associated with lower CD4+ cell count in treatment-experienced patients. AIDS. 2014 Sep 10; 28(14):2160-2. PMID: 25265081.
      Citations: 1     Fields:    Translation:HumansCells
    68. Loubet P, Charpentier C, Visseaux B, Nuta C, Adu E, Chapplain JM, Baysah M, Walters-Doe S, Tattevin P, Peytavin G, Yazdanpanah Y, Descamps D. Short communication: Prevalence of HIV-1 transmitted drug resistance in Liberia. AIDS Res Hum Retroviruses. 2014 Sep; 30(9):863-6. PMID: 24946849.
      Citations: 3     Fields:    Translation:HumansCells
    69. Charpentier C, Choquet M, Joly V, Yeni P, Visseaux B, Caseris M, Brun-Vézinet F, Yazdanpanah Y, Peytavin G, Descamps D, Landman R. Virological outcome at week 48 of three recommended first-line regimens using ultrasensitive viral load and plasma drug assay. J Antimicrob Chemother. 2014 Oct; 69(10):2819-25. PMID: 24948705.
      Citations: 2     Fields:    Translation:HumansCells
    70. Charpentier C, Eholié S, Anglaret X, Bertine M, Rouzioux C, Avettand-Fenoël V, Messou E, Minga A, Damond F, Plantier JC, Dabis F, Peytavin G, Brun-Vézinet F, Ekouevi DK. Genotypic resistance profiles of HIV-2-treated patients in West Africa. AIDS. 2014 May 15; 28(8):1161-9. PMID: 24583671.
      Citations: 20     Fields:    Translation:HumansCells
    71. Charpentier C, Joly V, Ghosn J, Yeni P, Raffi F, Descamps D, Morand-Joubert L. Change in HIV-1 DNA tropism despite virological success in patients receiving an enfuvirtide-based regimen. J Antimicrob Chemother. 2014 Sep; 69(9):2588-90. PMID: 24816213.
      Citations:    Fields:    Translation:HumansCells
    72. Charpentier C, Bertine M, Visseaux B, Leleu J, Larrouy L, Peytavin G, Mourez T, Collin G, Brun-Vézinet F, Plantier JC, Descamps D. In-vitro phenotypic susceptibility of HIV-1 'non-B' integrase inhibitors naive clinical isolates to dolutegravir and raltegravir. AIDS. 2013 Nov 28; 27(18):2959-61. PMID: 23942060.
      Citations: 2     Fields:    Translation:HumansCells
    73. Leoz M, Feyertag F, Charpentier C, Delaugerre C, Wirden M, Lemee V, Plantier JC. Characterization of CRF56_cpx, a new circulating B/CRF02/G recombinant form identified in MSM in France. AIDS. 2013 Sep 10; 27(14):2309-12. PMID: 24157908.
      Citations: 11     Fields:    Translation:HumansCells
    74. Landman R, Koulla-Shiro S, Sow PS, Ngolle M, Diallo MB, Guèye NF, Le Moing V, Eymard-Duvernay S, Benalycherif A, Charpentier C, Peytavin G, Delaporte E, Girard PM. Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial. Antivir Ther. 2014; 19(1):51-9. PMID: 23970206.
      Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
    75. Descamps D, Assoumou L, Chaix ML, Chaillon A, Pakianather S, de Rougemont A, Storto A, Dos Santos G, Krivine A, Delaugerre C, Montes B, Izopet J, Charpentier C, Wirden M, Maillard A, Morand-Joubert L, Pallier C, Plantier JC, Guinard J, Tamalet C, Cottalorda J, Marcelin AG, Desbois D, Henquell C, Calvez V, Brun-Vézinet F, Masquelier B, Costagliola D. National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011. J Antimicrob Chemother. 2013 Nov; 68(11):2626-31. PMID: 23798669.
      Citations: 9     Fields:    Translation:HumansCellsPHPublic Health
    76. Charpentier C, Visseaux B, Bénard A, Peytavin G, Damond F, Roy C, Taieb A, Chêne G, Matheron S, Brun-Vézinet F, Descamps D. Transmitted drug resistance in French HIV-2-infected patients. AIDS. 2013 Jun 19; 27(10):1671-4. PMID: 23595155.
      Citations: 2     Fields:    Translation:HumansCells
    77. Tang MW, Rhee SY, Bertagnolio S, Ford N, Holmes S, Sigaloff KC, Hamers RL, de Wit TF, Fleury HJ, Kanki PJ, Ruxrungtham K, Hawkins CA, Wallis CL, Stevens W, van Zyl GU, Manosuthi W, Hosseinipour MC, Ngo-Giang-Huong N, Belec L, Peeters M, Aghokeng A, Bunupuradah T, Burda S, Cane P, Cappelli G, Charpentier C, Dagnra AY, Deshpande AK, El-Katib Z, Eshleman SH, Fokam J, Gody JC, Katzenstein D, Koyalta DD, Kumwenda JJ, Lallemant M, Lynen L, Marconi VC, Margot NA, Moussa S, Ndung'u T, Nyambi PN, Orrell C, Schapiro JM, Schuurman R, Sirivichayakul S, Smith D, Zolfo M, Jordan MR, Shafer RW. Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine. J Infect Dis. 2013 Jun 15; 207 Suppl 2:S70-7. PMID: 23687292.
      Citations: 18     Fields:    Translation:HumansCells
    78. Charpentier C, Lambert-Niclot S, Visseaux B, Morand-Joubert L, Storto A, Larrouy L, Landman R, Calvez V, Marcelin AG, Descamps D. Evolution of the K65R, K103N and M184V/I reverse transcriptase mutations in HIV-1-infected patients experiencing virological failure between 2005 and 2010. J Antimicrob Chemother. 2013 Oct; 68(10):2197-8. PMID: 23749952.
      Citations: 7     Fields:    Translation:HumansCells
    79. Fourati S, Visseaux B, Armenia D, Morand-Joubert L, Artese A, Charpentier C, Van Den Eede P, Costa G, Alcaro S, Wirden M, Perno CF, Ceccherini Silberstein F, Descamps D, Calvez V, Marcelin AG. Identification of a rare mutation at reverse transcriptase Lys65 (K65E) in HIV-1-infected patients failing on nucleos(t)ide reverse transcriptase inhibitors. J Antimicrob Chemother. 2013 Oct; 68(10):2199-204. PMID: 23749955.
      Citations: 5     Fields:    Translation:HumansCells
    80. Charpentier C, Champenois K, Gervais A, Landman R, Joly V, Le Gac S, Larrouy L, Damond F, Brun-Vézinet F, Descamps D, Yazdanpanah Y. Predictive value of liver enzymes and inflammatory biomarkers for the severity of liver fibrosis stage in HIV/HCV co-infected patients. PLoS One. 2013; 8(3):e59205. PMID: 23527135.
      Citations: 3     Fields:    Translation:HumansCells
    81. Vallet S, Larrat S, Laperche S, Le Guillou-Guillemette H, Legrand-Abravanel F, Bouchardeau F, Pivert A, Henquell C, Mirand A, André-Garnier E, Giordanengo V, Lagathu G, Thibault V, Scholtes C, Schvoerer E, Gaudy-Graffin C, Maylin S, Trimoulet P, Brochot E, Hantz S, Gozlan J, Roque-Afonso AM, Soussan P, Plantier JC, Charpentier C, Chevaliez S, Colson P, Mackiewicz V, Aguilera L, Rosec S, Gouriou S, Magnat N, Lunel-Fabiani F, Izopet J, Morand P, Payan C, Pawlotsky JM. Multicenter quality control of hepatitis C virus protease inhibitor resistance genotyping. J Clin Microbiol. 2013 May; 51(5):1428-33. PMID: 23426922.
      Citations: 2     Fields:    Translation:Cells
    82. Charpentier C, Camacho R, Ruelle J, Kaiser R, Eberle J, Gürtler L, Pironti A, Stürmer M, Brun-Vézinet F, Descamps D, Obermeier M. HIV-2EU: supporting standardized HIV-2 drug resistance interpretation in Europe. Clin Infect Dis. 2013 Jun; 56(11):1654-8. PMID: 23429380.
      Citations: 12     Fields:    Translation:HumansCells
    83. Charpentier C, Lambert-Niclot S, Alteri C, Storto A, Flandre P, Svicher V, Perno CF, Brun-Vézinet F, Calvez V, Marcelin AG, Ceccherini-Silberstein F, Descamps D. Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes. PLoS One. 2013; 8(1):e54381. PMID: 23349869.
      Citations: 1     Fields:    Translation:HumansCells
    84. Charpentier C, Fagard C, Colin C, Katlama C, Molina JM, Jacomet C, Visseaux B, Taburet AM, Brun-Vézinet F, Chêne G, Yazdanpanah Y, Descamps D. Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial). PLoS One. 2013; 8(1):e53621. PMID: 23349724.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    85. Visseaux B, Charpentier C, Taieb A, Damond F, Bénard A, Larrouy L, Chêne G, Brun-Vézinet F, Matheron S, Descamps D. Concordance between HIV-2 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA. AIDS. 2013 Jan 14; 27(2):292-5. PMID: 23095312.
      Citations: 2     Fields:    Translation:HumansCells
    86. Larrouy L, Vivot A, Charpentier C, Bénard A, Visseaux B, Damond F, Matheron S, Chene G, Brun-Vezinet F, Descamps D. Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients. AIDS. 2013 Jan 02; 27(1):69-80. PMID: 23018441.
      Citations: 4     Fields:    Translation:HumansCells
    87. Soulié C, Charpentier C, Flandre P, Nino C, Carcelain G, Simon A, Katlama C, Landman R, Brun-Vézinet F, Descamps D, Calvez V, Marcelin AG. Natural evolution of CD4+ cell count in patients with CD4 >350 or >500? cells/mm3 at the time of diagnosis according to HIV-1 coreceptor tropism. J Med Virol. 2012 Dec; 84(12):1853-6. PMID: 23080487.
      Citations: 4     Fields:    Translation:HumansCells
    88. Joly V, Fagard C, Grondin C, Descamps D, Yazdanpanah Y, Charpentier C, Colin de Verdiere N, Tabuteau S, Raffi F, Cabie A, Chene G, Yeni P. Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo). Antimicrob Agents Chemother. 2013 Feb; 57(2):758-65. PMID: 23165467.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    89. Charpentier C, Joly V, Larrouy L, Fagard C, Visseaux B, de Verdière NC, Raffi F, Yeni P, Descamps D. Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial. J Antimicrob Chemother. 2013 Mar; 68(3):690-6. PMID: 23152480.
      Citations: 7     Fields:    Translation:HumansCells
    90. Thiébaut R, Charpentier C, Damond F, Taieb A, Antoine R, Capeau J, Chêne G, Collin G, Matheron S, Descamps D, Brun-Vézinet F. Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression. Clin Infect Dis. 2012 Nov 15; 55(10):1417-25. PMID: 22911639.
      Citations: 13     Fields:    Translation:HumansCells
    91. Kebe K, Thiam M, Diagne Gueye NR, Diop H, Dia A, Signate Sy H, Charpentier C, Belec L, Mboup S, Toure Kane C. High rate of antiretroviral drug resistance mutations in HIV type 1-infected Senegalese children in virological failure on first-line treatment according to the World Health Organization guidelines. AIDS Res Hum Retroviruses. 2013 Feb; 29(2):242-9. PMID: 22860571.
      Citations: 14     Fields:    Translation:HumansCells
    92. Lambert-Niclot S, Masquelier B, Cohen Codar I, Soulie C, Delaugerre C, Morand-Joubert L, Charpentier C, Ferre V, Plantier JC, Montes B, Carret S, Perrot V, Peytavin G, Costagliola D, Calvez V, Marcelin AG. Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice. J Antimicrob Chemother. 2012 Oct; 67(10):2487-93. PMID: 22733652.
      Citations:    Fields:    Translation:HumansCells
    93. Charpentier C, Landman R, Laouénan C, Joly V, Hamet G, Damond F, Brun-Vézinet F, Mentré F, Descamps D, Yeni P. Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome. J Antimicrob Chemother. 2012 Sep; 67(9):2231-5. PMID: 22643190.
      Citations: 17     Fields:    Translation:HumansCells
    94. Fagard C, Colin C, Charpentier C, Rami A, Jacomet C, Yeni P, Vittecoq D, Katlama C, Molina JM, Descamps D, Chêne G, Yazdanpanah Y. Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial. J Acquir Immune Defic Syndr. 2012 Apr 15; 59(5):489-93. PMID: 22293546.
      Citations: 14     Translation:Humans
    95. Charpentier C, Larrouy L, Visseaux B, Landman R, Levittas M, Storto A, Damond F, Yazdanpanah Y, Yeni P, Brun-Vézinet F, Descamps D. Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients. J Antimicrob Chemother. 2012 Jun; 67(6):1459-61. PMID: 22382470.
      Citations: 5     Fields:    Translation:HumansCells
    96. Visseaux B, Hurtado-Nedelec M, Charpentier C, Collin G, Storto A, Matheron S, Larrouy L, Damond F, Brun-Vézinet F, Descamps D. Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool. J Infect Dis. 2012 Jan 01; 205(1):111-20. PMID: 22140264.
      Citations: 11     Fields:    Translation:HumansCells
    97. Larrouy L, Charpentier C, Landman R, Capitant C, Chazallon C, Yeni P, Peytavin G, Damond F, Brun-Vezinet F, Descamps D. Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimen. AIDS. 2011 Nov 13; 25(17):2143-8. PMID: 21904187.
      Citations: 2     Fields:    Translation:HumansCells
    98. Visseaux B, Charpentier C, Hurtado-Nedelec M, Storto A, Antoine R, Peytavin G, Damond F, Matheron S, Brun-Vézinet F, Descamps D. In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors. Antimicrob Agents Chemother. 2012 Jan; 56(1):137-9. PMID: 22064539.
      Citations: 8     Fields:    Translation:HumansCells
    99. Péré H, Charpentier C, Mbelesso P, Dandy M, Matta M, Moussa S, De Dieu Longo J, Grésenguet G, Abraham B, Bélec L. Virological response and resistance profiles after 24 months of first-line antiretroviral treatment in adults living in Bangui, Central African Republic. AIDS Res Hum Retroviruses. 2012 Apr; 28(4):315-23. PMID: 21942692.
      Citations: 5     Fields:    Translation:HumansCells
    100. Malet I, Fourati S, Charpentier C, Morand-Joubert L, Armenia D, Wirden M, Sayon S, Van Houtte M, Ceccherini-Silberstein F, Brun-Vézinet F, Perno CF, Descamps D, Capt A, Calvez V, Marcelin AG. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype. J Antimicrob Chemother. 2011 Dec; 66(12):2827-30. PMID: 21933786.
      Citations: 17     Fields:    Translation:HumansCells
    101. Ni XJ, Delelis O, Charpentier C, Storto A, Collin G, Damond F, Descamps D, Mouscadet JF. G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not. Retrovirology. 2011 Aug 19; 8:68. PMID: 21854605.
      Citations: 14     Fields:    Translation:HumansCells
    102. Bélec L, Jenabian MA, Charpentier C, Saïdi H. Combinatorial prevention of HIV transmission in women: the case for a vaginal microbicide. Future Microbiol. 2011 Jul; 6(7):731-7. PMID: 21797688.
      Citations: 4     Fields:    Translation:Humans
    103. Charpentier C, Gody JC, Mbitikon O, Moussa S, Matta M, Péré H, Fournier J, Longo Jde D, Bélec L. Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: a cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. AIDS Res Hum Retroviruses. 2012 Jan; 28(1):87-94. PMID: 21599597.
      Citations: 18     Fields:    Translation:HumansCells
    104. Charpentier C, Lambert-Niclot S, Larrouy L, Peytavin G, Valantin MA, Landman R, Katlama C, Yeni P, Felices M, Brun-Vézinet F, Calvez V, Marcelin AG, Descamps D. Impact of adding enfuvirtide to the predictive value of the darunavir genotypic resistance score. J Acquir Immune Defic Syndr. 2011 May 01; 57(1):e15-7. PMID: 21734472.
      Citations:    Translation:HumansCells
    105. Masquelier B, Taieb A, Reigadas S, Marchou B, Cheneau C, Spire B, Charpentier C, Leport C, Raffi F, Chêne G, Descamps D. Cellular HIV-1 DNA quantification and short-term and long-term response to antiretroviral therapy. J Antimicrob Chemother. 2011 Jul; 66(7):1582-9. PMID: 21525020.
      Citations: 4     Fields:    Translation:HumansCells
    106. Charpentier C, Gody JC, Tisserand P, Matta M, Fournier J, Mbitikon O, Bélec L. Usefulness of a genotypic resistance test using dried blood spot specimens in African HIV-infected children with virological failure according to the 2010-revised WHO criteria. Arch Virol. 2011 Sep; 156(9):1603-6. PMID: 21479946.
      Citations: 8     Fields:    Translation:HumansCells
    107. Charpentier C, Jenabian MA, Piketty C, Karmochkine M, Tisserand P, Laureillard D, Bélec L, Si-Mohamed A, Weiss L. Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy. Scand J Infect Dis. 2011 May; 43(5):373-9. PMID: 21341978.
      Citations:    Fields:    Translation:HumansCells
    108. Charpentier C, Koyalta D, Ndinaromtan M, Tchobkréo B, Jenabian MA, Day N, Si-Mohamed A, Weiss H, Bélec L. Distribution of HIV-1 and HSV-2 epidemics in Chad revealing HSV-2 hot-spot in regions of high-risk HIV spread. J Infect Dev Ctries. 2011 Feb 01; 5(1):64-7. PMID: 21330743.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    109. Depatureaux A, Charpentier C, Leoz M, Unal G, Damond F, Kfutwah A, Vessière A, Simon F, Plantier JC. Impact of HIV-1 group O genetic diversity on genotypic resistance interpretation by algorithms designed for HIV-1 group M. J Acquir Immune Defic Syndr. 2011 Feb 01; 56(2):139-45. PMID: 21233638.
      Citations: 7     Translation:HumansCells
    110. Larrouy L, Lambert-Niclot S, Charpentier C, Fourati S, Visseaux B, Soulié C, Wirden M, Katlama C, Yeni P, Brun-Vézinet F, Calvez V, Marcelin AG, Descamps D. Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavir. Antimicrob Agents Chemother. 2011 Apr; 55(4):1754-7. PMID: 21282435.
      Citations: 4     Fields:    Translation:Cells
    111. Charpentier C, Bellecave P, Cisse M, Mamadou S, Diakite M, Peytavin G, Tchiombiano S, Teisseire P, Pizarro L, Storto A, Brun-Vézinet F, Katlama C, Calvez V, Marcelin AG, Masquelier B, Descamps D. High prevalence of antiretroviral drug resistance among HIV-1-untreated patients in Guinea-Conakry and in Niger. Antivir Ther. 2011; 16(3):429-33. PMID: 21555827.
      Citations: 15     Fields:    Translation:HumansCells
    112. Launay O, Tod M, Tschöpe I, Si-Mohamed A, Bélarbi L, Charpentier C, Goujard C, Taburet AM, Lortholary O, Leroy V, Bélec L. Residual HIV-1 RNA and HIV-1 DNA production in the genital tract reservoir of women treated with HAART: the prospective ANRS EP24 GYNODYN study. Antivir Ther. 2011; 16(6):843-52. PMID: 21900716.
      Citations: 22     Fields:    Translation:HumansCellsCTClinical Trials
    113. Charpentier C, Larrouy L, Matheron S, Damond F, Delelis O, Mouscadet JF, Campa P, Chêne G, Brun-Vézinet F, Descamps D. Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal. Antivir Ther. 2011; 16(6):937-40. PMID: 21900727.
      Citations: 3     Fields:    Translation:HumansCells
    114. Charpentier C, Gody JC, Tisserand P, Matta M, Péré H, Fournier J, Mbitikon O, Bélec L. Surveillance of antiretroviral drug resistance mutations in untreated young children living in the Central African Republic. Antivir Ther. 2011; 16(8):1347-50. PMID: 22155917.
      Citations: 7     Fields:    Translation:HumansCellsPHPublic Health
    115. Charpentier C, Roquebert B, Delelis O, Larrouy L, Matheron S, Tubiana R, Karmochkine M, Duval X, Chêne G, Storto A, Collin G, Bénard A, Damond F, Mouscadet JF, Brun-Vézinet F, Descamps D. Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir. Antimicrob Agents Chemother. 2011 Mar; 55(3):1293-5. PMID: 21189351.
      Citations: 11     Fields:    Translation:HumansCells
    116. Charpentier C, Larrouy L, Collin G, Damond F, Matheron S, Chêne G, Nie T, Schinazi R, Brun-Vézinet F, Descamps D. In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572. AIDS. 2010 Nov 13; 24(17):2753-5. PMID: 20827161.
      Citations: 13     Fields:    Translation:HumansCells
    117. Charpentier C, Roquebert B, Colin C, Taburet AM, Fagard C, Katlama C, Molina JM, Jacomet C, Brun-Vézinet F, Chêne G, Yazdanpanah Y, Descamps D. Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen. AIDS. 2010 Nov 13; 24(17):2651-6. PMID: 20802293.
      Citations: 7     Fields:    Translation:HumansCellsCTClinical Trials
    118. Charpentier C, Talla F, Nguepi E, Si-Mohamed A, Bélec L. Virological failure and HIV type 1 drug resistance profiles among patients followed-up in private sector, Douala, Cameroon. AIDS Res Hum Retroviruses. 2011 Feb; 27(2):221-30. PMID: 20977359.
      Citations: 3     Fields:    Translation:HumansCells
    119. Descamps D, Chaix ML, Montes B, Pakianather S, Charpentier C, Storto A, Barin F, Dos Santos G, Krivine A, Delaugerre C, Izopet J, Marcelin AG, Maillard A, Morand-Joubert L, Pallier C, Plantier JC, Tamalet C, Cottalorda J, Desbois D, Calvez V, Brun-Vezinet F, Masquelier B, Costagliola D. Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France. J Antimicrob Chemother. 2010 Dec; 65(12):2620-7. PMID: 20965891.
      Citations: 20     Fields:    Translation:HumansCells
    120. Charpentier C, Weiss L. Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy. Infect Drug Resist. 2010; 3:103-14. PMID: 21694899.
      Citations: 1     
    121. Depatureaux A, Charpentier C, Collin G, Leoz M, Descamps D, Vessière A, Damond F, Rousset D, Brun-Vézinet F, Plantier JC. Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide. Antimicrob Agents Chemother. 2010 Sep; 54(9):4016-9. PMID: 20547806.
      Citations: 5     Fields:    Translation:HumansCells
    122. Jenabian MA, Saïdi H, Charpentier C, Bouhlal H, Schols D, Balzarini J, Bell TW, Vanham G, Bélec L. Differential activity of candidate microbicides against early steps of HIV-1 infection upon complement virus opsonization. AIDS Res Ther. 2010 Jun 14; 7:16. PMID: 20546571.
      Citations: 1     Fields:    
    123. Recordon-Pinson P, Soulié C, Flandre P, Descamps D, Lazrek M, Charpentier C, Montes B, Trabaud MA, Cottalorda J, Schneider V, Morand-Joubert L, Tamalet C, Desbois D, Macé M, Ferré V, Vabret A, Ruffault A, Pallier C, Raymond S, Izopet J, Reynes J, Marcelin AG, Masquelier B. Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study. Antimicrob Agents Chemother. 2010 Aug; 54(8):3335-40. PMID: 20530226.
      Citations: 30     Fields:    Translation:HumansCells
    124. Charpentier C, Laureillard D, Piketty C, Tisserand P, Batisse D, Karmochkine M, Si-Mohamed A, Weiss L. High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors. AIDS. 2010 Mar 27; 24(6):867-73. PMID: 20160635.
      Citations: 21     Fields:    Translation:Humans
    125. Stegmann S, Manea ME, Charpentier C, Damond F, Karmochkine M, Laureillard D, Si-Mohamed A, Weiss L, Piketty C. Foscarnet as salvage therapy in HIV-2-infected patient with antiretroviral treatment failure. J Clin Virol. 2010 Jan; 47(1):79-81. PMID: 19962343.
      Citations: 5     Fields:    Translation:HumansCells
    126. Marcelin AG, Flandre P, Descamps D, Morand-Joubert L, Charpentier C, Izopet J, Trabaud MA, Saoudin H, Delaugerre C, Tamalet C, Cottalorda J, Bouvier-Alias M, Bettinger D, Dos Santos G, Ruffault A, Alloui C, Henquell C, Rogez S, Barin F, Signori-Schmuck A, Vallet S, Masquelier B, Calvez V. Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients. Antimicrob Agents Chemother. 2010 Jan; 54(1):72-7. PMID: 19901096.
      Citations: 11     Fields:    Translation:HumansCells
    127. Jenabian MA, Saïdi H, Charpentier C, Van Herrewege Y, Son JC, Schols D, Balzarini J, Vanham G, Bélec L. In vitro synergistic activity against CCR5-tropic HIV-1 with combinations of potential candidate microbicide molecules HHA, KRV2110 and enfuvirtide (T20). J Antimicrob Chemother. 2009 Dec; 64(6):1192-5. PMID: 19875507.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    128. Fransen S, Karmochkine M, Huang W, Weiss L, Petropoulos CJ, Charpentier C. Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure. Antimicrob Agents Chemother. 2009 Oct; 53(10):4522-4. PMID: 19667293.
      Citations: 27     Fields:    Translation:HumansCells
    129. Koyalta D, Charpentier C, Beassamda J, Rey E, Si-Mohamed A, Djemadji-Oudjeil N, Bélec L. High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. Clin Infect Dis. 2009 Jul 01; 49(1):155-9. PMID: 19480574.
      Citations: 15     Fields:    Translation:HumansCells
    130. Gody JC, Charpentier C, Mbitikon O, Si-Mohamed A, LeGoff J, Grésenguet G, Bélec L. High prevalence of antiretroviral drug resistance mutations in HIV-1 non-B subtype strains from African children receiving antiretroviral therapy regimen according to the 2006 revised WHO recommendations. J Acquir Immune Defic Syndr. 2008 Dec 15; 49(5):566-9. PMID: 19202461.
      Citations: 13     Translation:HumansCells
    131. Charpentier C, Laureillard D, Sodqi M, Si-Mohamed A, Karmochkine M, Bélec L, Weiss L, Piketty C. Foscarnet salvage therapy efficacy is associated with the presence of thymidine-associated mutations (TAMs) in HIV-infected patients. J Clin Virol. 2008 Oct; 43(2):212-5. PMID: 18760662.
      Citations: 1     Fields:    Translation:HumansCells
    132. Marcelin AG, Masquelier B, Descamps D, Izopet J, Charpentier C, Alloui C, Bouvier-Alias M, Signori-Schmuck A, Montes B, Chaix ML, Amiel C, Santos GD, Ruffault A, Barin F, Peytavin G, Lavignon M, Flandre P, Calvez V. Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2008 Sep; 52(9):3237-43. PMID: 18625773.
      Citations: 15     Fields:    Translation:HumansCells
    133. Nora T, Bouchonnet F, Labrosse B, Charpentier C, Mammano F, Clavel F, Hance AJ. Functional diversity of HIV-1 envelope proteins expressed by contemporaneous plasma viruses. Retrovirology. 2008 Feb 29; 5:23. PMID: 18312646.
      Citations: 8     Fields:    Translation:HumansCells
    134. Nora T, Charpentier C, Tenaillon O, Hoede C, Clavel F, Hance AJ. Contribution of recombination to the evolution of human immunodeficiency viruses expressing resistance to antiretroviral treatment. J Virol. 2007 Jul; 81(14):7620-8. PMID: 17494080.
      Citations: 52     Fields:    Translation:HumansCells
    135. Chomont N, Hocini H, Grésenguet G, Brochier C, Bouhlal H, Andréoletti L, Becquart P, Charpentier C, de Dieu Longo J, Si-Mohamed A, Kazatchkine MD, Bélec L. Early archives of genetically-restricted proviral DNA in the female genital tract after heterosexual transmission of HIV-1. AIDS. 2007 Jan 11; 21(2):153-62. PMID: 17197805.
      Citations: 12     Fields:    Translation:HumansCells
    136. Si-Mohamed A, Piketty C, Tisserand P, LeGoff J, Weiss L, Charpentier C, Kazatchkine MD, Bélec L. Increased polymorphism in the HR-1 gp41 env gene encoding the enfuvirtide (T-20) target in HIV-1 variants harboring multiple antiretroviral drug resistance mutations in the pol gene. J Acquir Immune Defic Syndr. 2007 Jan 01; 44(1):1-5. PMID: 17075396.
      Citations: 1     Translation:HumansCells
    137. Charpentier C, Nora T, Tenaillon O, Clavel F, Hance AJ. Extensive recombination among human immunodeficiency virus type 1 quasispecies makes an important contribution to viral diversity in individual patients. J Virol. 2006 Mar; 80(5):2472-82. PMID: 16474154.
      Citations: 62     Fields:    Translation:HumansCells
    138. Morand-Joubert L, Charpentier C, Poizat G, Chêne G, Dam E, Raguin G, Taburet AM, Girard PM, Hance AJ, Clavel F. Low genetic barrier to large increases in HIV-1 cross-resistance to protease inhibitors during salvage therapy. Antivir Ther. 2006; 11(2):143-54. PMID: 16640095.
      Citations: 5     Fields:    Translation:HumansCells
    139. Charpentier C, Dwyer DE, Mammano F, Lecossier D, Clavel F, Hance AJ. Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors. J Virol. 2004 Apr; 78(8):4234-47. PMID: 15047838.
      Citations: 26     Fields:    Translation:HumansCells
    Charpentier's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (199)
    Explore
    _
    Co-Authors (151)
    Explore
    _
    Similar People (60)
    Explore
    _